The Accuracy of Fecal Calprotectin in Detecting Esophageal Varices in Egyptian Patients With Liver Cirrhosis

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The goal of this cross-sectional observational study is to evaluate the accuracy of fecal calprotectin versus non-invasive scores in assessing the presence and grading of esophageal varices in Egyptian patients. Researchers will compare fecal calprotectin levels in cirrhotic patients with and without esophageal varices (EVs) and healthy subjects. researchers will also evaluate the performance of fecal calprotectin, AST to platelet ratio index (APRI) score, fibrosis-4 (FIB-4) score, albumin-bilirubin (ALBI) score, platelet-albumin-bilirubin (PALBI) score, and platelet-spleen diameter ratio (PSR) for predicting esophageal varices. Participants will undergo history-taking, clinical examination, laboratory investigations, fecal calprotectin, abdominal ultrasonography, and upper endoscopy. Endoscopic grading of esophageal varices will be done using Paquet's classification. The APRI, FIB-4, ALBI, PALBI, and PSR scores will be calculated. The performance of fecal calprotectin for predicting EVs will be compared versus other non-invasive scores.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Age ≥18 years

• Liver cirrhosis

Locations
Other Locations
Egypt
Tanta University Hospitals
RECRUITING
Tanta
Contact Information
Primary
Rania M Elkafoury, MD
rania.elkafoury@med.tanta.edu.eg
+201004672358
Backup
Nabila A Elgazzar, MD
nabilaelgazzar@med.tanta.edu.eg
00201288585733
Time Frame
Start Date: 2024-12-01
Estimated Completion Date: 2025-12
Participants
Target number of participants: 156
Treatments
cirrhotic patients with esophageal varices
52 cirrhotic patients with esophageal varices.
cirrhotic patients without esophageal varices
52 cirrhotic patients without esophageal varices.
control group
52 healthy subjects as a control.
Sponsors
Leads: Tanta University

This content was sourced from clinicaltrials.gov